KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Intangibles (2016 - 2025)

Historic Intangibles for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $37.8 billion.

  • Astrazeneca's Intangibles rose 179.95% to $37.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $37.8 billion, marking a year-over-year increase of 179.95%. This contributed to the annual value of $37.8 billion for FY2025, which is 179.95% up from last year.
  • As of Q4 2025, Astrazeneca's Intangibles stood at $37.8 billion, which was up 179.95% from $38.2 billion recorded in Q3 2025.
  • Astrazeneca's Intangibles' 5-year high stood at $70.6 billion during Q4 2021, with a 5-year trough of $20.0 billion in Q2 2021.
  • Over the past 5 years, Astrazeneca's median Intangibles value was $38.6 billion (recorded in 2023), while the average stood at $38.7 billion.
  • In the last 5 years, Astrazeneca's Intangibles skyrocketed by 33960.19% in 2021 and then crashed by 4435.04% in 2022.
  • Quarter analysis of 5 years shows Astrazeneca's Intangibles stood at $70.6 billion in 2021, then crashed by 44.35% to $39.3 billion in 2022, then fell by 3.1% to $38.1 billion in 2023, then fell by 2.39% to $37.2 billion in 2024, then grew by 1.8% to $37.8 billion in 2025.
  • Its Intangibles stands at $37.8 billion for Q4 2025, versus $38.2 billion for Q3 2025 and $37.9 billion for Q2 2025.